Glaxosmithkline Share News (GSK)

UPDATE 2-Roche boosted by strong drug sales in U.S. and China

* Q3 sales 11.57 bln Swiss francs vs forecast 11.54 bln * Healthy uptake of new drugs Perjeta and Kadcyla * CEO says growth in China still strong * Confirms full-year outlook By Caroline Copley ZURICH, Oct 17 (Reuters) - Strong demand for Roche's speciality cancer m

UPDATE 2-U.S. FDA panel votes against expanded use of Amarin drug

(Adds analyst comment in paragraph 7) By Toni Clarke Oct 16 (Reuters) - Amarin Corporation Plc's triglyceride-lowering drug Vascepa should not be approved for use in a broader patient population until results from an additional study have been analyzed, an advisory panel to the U.S.

U.S. FDA panel votes against expanded use of Amarin drug

Oct 16 (Reuters) - Amarin Corporation Plc's triglyceride-lowering drug Vascepa should not be approved for use in a broader patient population, an advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 9-2 against approval of Vascepa for use in combinatio

GSK's Reilly assisting anti-bribery authorities in China

By Ben Hirschler LONDON, Oct 16 (Reuters) - Mark Reilly, GlaxoSmithKline's former head of operations in China, is helping anti-corruption officials in the country who are investigating allegations of extensive bribery by the drugmaker. One person familiar with the situation said Reil

DIRECTOR DEALINGS: GlaxoSmithKline Executive's Relation Allocated ADSs

MARKET PULSE- Facebook, AMD, Netflix, Coronado Biosciences, Mannkind

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) U.S. stocks fell at the open on Monday as traders focused on events in Washington after weekend talks between Republicans and Democrats left the risk of a possible

MARKET PULSE- Facebook, AMD, Netflix, Merck, Newmont Mining, Mannkind

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) Wall Street was set for a lower open on Monday, focused on events in Washington after weekend talks between Republicans and Democrats showed some progress but left

DIRECTOR DEALINGS: GlaxoSmithKline Executive Reinvests Dividend, Buys Shares

MARKET PULSE- Facebook, AMD, Netflix, Merck, ArcelorMittal, Mannkind

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) U.S. stock index futures sank on Monday after weekend talks between Republicans and Democrats failed to conclude an agreement to reopen the federal government and

MARKET PULSE- Facebook, Netflix, Merck, ArcelorMittal, Expedia

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) U.S. stock index futures fell on Monday as continuous gridlock in Washington was likely to resume selling pressure in equities as there were no guarantees the fede

DIRECTOR DEALINGS: GlaxoSmithKline Executives Acquire Shares

DIRECTOR DEALINGS: Glaxo Directors Acquire Shares Via Dividend Re-Investment

Broker tips: Standard Life, GlaxoSmithKline, Whitbread

JPMorgan Cazenove has reiterated its 'overweight' rating and 430p target price for insurance group Standard Life, adding the stock to its European 'Analyst Focus List'. The bank pointed out that the stock has been under pressure since the start of the week, partly due to erroneous data implying net

Broker snap: Generic competition fears ease at Glaxo, says Panmure

GlaxoSmithKline's share price edged higher on Friday morning on hopes that generic versions of its best-selling drug Advair may not come to market until later than expected - something that Panmure Gordon believes is a reason to 'buy' the UK-listed stock. The broker highlighted comments from Teva,

Genmab announces positive results for sclerosis drug candidate

COPENHAGEN, Oct 10 (Reuters) - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab. In a randomised study of 232 patients with relapsing-remitting multiple sclerosis, treatment with ofatumumab significantly redu